Comparison · NCT04256421-sae
Placebo + Atezolizumab vs Tiragolumab + Atezolizumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Placebo + Atezolizumab vs Tiragolumab + Atezolizumab: serious adverse events. Trial comparisons, record NCT04256421-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04256421-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.423 | 0.363 | 0.485 | wilson | |
| Risk in group 2 | 0.452 | 0.39 | 0.515 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0291 | -0.116 | 0.0588 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.936 | 0.764 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 0.888 | 0.62 | 1.27 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Placebo + Atezolizumab than on Tiragolumab + Atezolizumab | 34.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Placebo + Atezolizumab | During induction treatment participants received atezolizumab, 1200 milligram (mg) followed by placebo and carboplatin, as intravenous (IV) infusion, to achieve an initial target area under the concentration-time curve (AUC) of 5 milligram/milliliter/minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 cycles. Etoposide 100 milligram per square meter (mg/m\^2) was also administered as IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles. Participants then received maintenance treatment with atezolizumab+ placebo on Day 1 of each 21-day cycle at the same dose as during induction treatment until disease progression or loss of clinical benefit. | 104 | 246 | EG000 |
| Group 2 | Tiragolumab + Atezolizumab | During induction treatment participants received atezolizumab, 1200 mg followed by tiragolumab, 600mg and carboplatin, as IV infusion, to achieve an initial target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle for 4 cycles. Etoposide 100 mg/m\^2 was also administered as IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles. Participants then received maintenance treatment with atezolizumab+ tiragolumab on Day 1 of each 21-day cycle at the same dose as during induction treatment until disease progression or loss of clinical benefit. | 108 | 239 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to approximately 24 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- NCT number
- NCT04256421
- Phases
- PHASE3
- Conditions
- Small Cell Lung Cancer
- Interventions
- Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Placebo
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2025-10-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04256421?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04256421-sae